Sign up USA
Proactive Investors - Run By Investors For Investors

Trading in Trevena shares halted as FDA reviews company's pain treatment drug

The regulator is due to make a decision whether to approve the drug's use in November
An injection
Trevena is a biopharmaceutical company focused on pain treatments

Trading in the shares of Trevena Inc (NASDAQ:TRVN) were halted on Thursday because the US Food and Drug Administration’s is reviewing its pain drug for adult patients.

The government's Anesthetic and Analgesic Drug Products Advisory Committee (AADPAC) is meeting all day to review oliceridine, a product developed by Trevena for the management of moderate to severe acute pain in adult patients for whom an intravenous (IV) opioid is warranted. 

Trevena’s New Drug Application (NDA) submission for oliceridine was accepted by the FDA on January 2, 2018, with a PDUFA target date for completion of review by the FDA of November 2, 2018.

The AADPAC reviews and evaluates available data concerning the safety and effectiveness of marketed drug products for use in anesthesiology and surgery and makes recommendations to the FDA. 

READ: Trevena shares pop on successful completion of Phase 1 study of acute migraine treatment

The FDA is not bound by the Advisory Committee’s recommendations but takes its advice into consideration when making its decisions.

Oliceridine is a G-protein biased mu-opioid receptor (MOR) ligand in development to manage moderate to severe acute pain in hospitals or other controlled clinical settings and where intravenous (IV) therapy is justified.

Shares of Trevena were trading very early in the premarket on Thursday at $0.94, having closed on Wednesday 11.5% down at $0.947.

Trevena is a biopharmaceutical company focused on the development and commercialization of new treatment options for patients in pain.

The company is based in Chesterbrook, Pennsylvania.

View full TRVN profile View Profile

Trevena Timeline

Related Articles

June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
Once the phase III trial is completed, Futura plans to either sell off the asset or find a partner
September 26 2018
The pharma group expects to dose the first patient in the Phase III trial of its MED2002 erectile dysfunction treatment within the next month

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use